Policy

Insights

Browse all insights

News

Browse all news

BIO Statement on Passage of the Reconciliation Package

July 3, 2025

Massachusetts Governor Maura Healey Named BIO’s Governor of the Year

June 17, 2025

BIO Elects Genentech’s Fritz Bittenbender as New Board Chair

June 16, 2025

BIO International Convention Opens in Boston, Showcasing Global Innovation in Biotechnology

June 16, 2025

Letters, Comments & Testimony

CSBA Letter to Congressional Leadership Supporting R&D Tax Expensing Legislation

May 29, 2025

John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s Executive Order on most favored nation:

May 12, 2025

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s biotechnology leadership.“Importing socialized…

CSBA Letter to Congressional Leadership on Most Favored Nation Foreign Reference Pricing

May 8, 2025

Co-Pay Accumulator Programs

Insurers and PBMs are implementing “co-pay accumulator” programs – an effort to prevent funds provided by manufacturer assistance programs from…

International Reference Pricing

Adopting foreign price controls on innovative medicines would severely chill investment in new cures and therapies for diseases and jeopardize access…